Table 1 Clinical characteristics
| Â | Overall | BP-SES | DP-EES | p value |
|---|---|---|---|---|
n = 141 | n = 44 | n = 100 | ||
Age, years | 70 (62–77) | 67 (57–78) | 70 (64–77) | 0.278 |
Male, n (%) | 115 (81.6) | 32 (72.7) | 85 (85.0) | 0.082 |
Body mass index | 24.7 (22.0–27.1) | 24.8 (22.4–26.7) | 23.8 (22.4–26.7) | 0.856 |
Follow-up duration, days | 386 (334–472) | 377 (308–435) | 390 (347–484) | 0.139 |
Risk factor, n (%) | ||||
 Hypertension | 122 (86.5) | 40 (90.9) | 85 (85.0) | 0.335 |
 Dyslipidemia | 109 (77.3) | 35 (79.6) | 76 (76.0) | 0.641 |
 Chronic kidney disease | 87 (61.7) | 25 (56.8) | 64 (64.0) | 0.414 |
 Hemodialysis | 21 (14.9) | 6 (13.6) | 15 (15.0) | 0.831 |
 Smoking | 25 (17.9) | 10 (22.7) | 15 (15.2) | 0.271 |
 Family history of IHD | 36 (26.1) | 14 (32.6) | 23 (23.5) | 0.259 |
 Previous myocardial infarction | 42 (29.8) | 9 (20.5) | 35 (35.0) | 0.081 |
 Previous PCI | 59 (41.9) | 15 (34.1) | 47 (47.0) | 0.150 |
 Previous CABG | 5 (3.5) | 3 (6.8) | 2 (2.0) | 0.146 |
Medication at PCI, n (%) | ||||
 Aspirin | 125 (88.7) | 37 (84.1) | 90 (90.0) | 0.311 |
 Thienopyridine | 114 (80.9) | 31 (70.5) | 86 (86.0) | 0.028 |
 Statin | 116 (82.3) | 36 (81.8) | 83 (83.0) | 0.863 |
 ACEI/ARB | 109 (77.3) | 30 (68.2) | 81 (81.0) | 0.092 |
 Beta blocker | 93 (66.0) | 22 (50.0) | 74 (74.0) | 0.005 |
 Calcium channel blocker | 70 (49.6) | 19 (43.2) | 51 (51.0) | 0.387 |
 Insulin | 26 (18.6) | 6 (14.0) | 21 (21.0) | 0.324 |
Laboratory findings | ||||
 Triglycerides, mg/dL | 125 (92–185) | 116 (91–176) | 125 (92–197) | 0.284 |
 LDL-C, mg/dL | 85 (67–109) | 90 (68–107) | 80 (66–112) | 0.700 |
 HDL-C, mg/dL | 49 (41–58) | 51 (42–66) | 48 (40–57) | 0.112 |
 HbA1c, % | 6.8 (6.3–7.3) | 6.8 (6.3–7.4) | 6.8 (6.3–7.3) | 0.907 |
 eGFR, mL/min/1.73 m2 | 52 (34–64) | 55 (35–67) | 51 (32–63) | 0.253 |
 BNP, pg/mL | 108 (46–322) | 79 (27–299) | 115 (54–350) | 0.108 |
 Left ventricular ejection fraction, % | 60 (50–65) | 61 (51–66) | 59 (50–65) | 0.293 |